Join Us in Changing Lives At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we are looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. We are currently recruiting for a Director, Commercial Excellence to join our Global Commercial Operations Team from one of our locations in either Oxford (UK), Lyon or Strasbourg (France) or Bedford, Massachusetts. In this role, you will develop, implement, and own high impact business processes and tools to deliver client project successfully playing a key part in advancing our mission and making a real difference. Your responsibilities in this role will be: • Implement, manage,and own important enabling processes embedded into Lead-To-Order process which aim to improve our commercial efficiency and customer satisfaction. • Support processes related to capacity analysis and planning model that positions OXB teams and resources for success. • The creation and measuring of Key performance Indicators which monitor our practices, support strategic decisions and influence behaviours. • Create, implement, and maintain tools, methodology and processes related to key services / work packages that are part of our offering such as - but not limited to - cost model and profitability analysis by liaising with operations teams and finance. • Create and maintain a playbook for key commercial activities including document/ template naming and numbering scheme for consistency and clarity. • Benchmark from industry best practices and identify process improvement opportunities and tools related to all commercial team activities. We are Looking For: • Educated to degree level ideally within Life Sciences. • A professional qualification within Project Management or Operational Excellence would be advantageous. • Knowledge and experience in the overall structure of process development and GMP manufacturing projects in Pharma & Biotech • Proven operational experience within the Biotech-Pharma industry including experience and/or an appreciation of Business Development & Commercial activities within a CDMO or other similar pharmaceutical services organisation. • Some knowledge and experience within Cell & Gene therapy manufacture is an advantage. • Experience and knowledge of leading process improvement programmes and the associated methodologies. • A good understanding of the key business drivers and financial aspects of service-based partnerships is desirable. • Knowledge and acumen within with customer relationship management (CRM) platforms such as Salesforce. • Strong analytical and technology skills, including proficiency in project planning tools, and MS Office suite. • The ability to communicate and influence cross departmentally and internationally across OXB globally. About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors—the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), and adenoviral vectors. Our world-class capabilities span from early-stage development to commercialisation, supported by robust quality-assurance systems, analytical methods, and regulatory expertise. Why Join Us? Competitive total reward packages Wellbeing programmes that support your mental and physical health Career development opportunities to help you grow and thrive Supportive, inclusive, and collaborative culture State-of-the-art labs and manufacturing facilities A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, we are future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.